These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 30383417)

  • 1. Gaps in Preexposure Prophylaxis Uptake for HIV Prevention in the Veterans Health Administration.
    Garner W; Wilson BM; Beste L; Maier M; Ohl ME; Van Epps P
    Am J Public Health; 2018 Nov; 108(S4):S305-S310. PubMed ID: 30383417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brief Report: Incidence of HIV in a Nationwide Cohort Receiving Pre-exposure Prophylaxis for HIV Prevention.
    Van Epps P; Wilson BM; Garner W; Beste LA; Maier MM; Ohl ME
    J Acquir Immune Defic Syndr; 2019 Dec; 82(5):427-430. PubMed ID: 31714421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uptake of HIV Preexposure Prophylaxis Among Commercially Insured Persons-United States, 2010-2014.
    Wu H; Mendoza MC; Huang YA; Hayes T; Smith DK; Hoover KW
    Clin Infect Dis; 2017 Jan; 64(2):144-149. PubMed ID: 27986691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study.
    Grinsztejn B; Hoagland B; Moreira RI; Kallas EG; Madruga JV; Goulart S; Leite IC; Freitas L; Martins LMS; Torres TS; Vasconcelos R; De Boni RB; Anderson PL; Liu A; Luz PM; Veloso VG;
    Lancet HIV; 2018 Mar; 5(3):e136-e145. PubMed ID: 29467098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prevalence of pre-exposure prophylaxis use and the pre-exposure prophylaxis-to-need ratio in the fourth quarter of 2017, United States.
    Siegler AJ; Mouhanna F; Giler RM; Weiss K; Pembleton E; Guest J; Jones J; Castel A; Yeung H; Kramer M; McCallister S; Sullivan PS
    Ann Epidemiol; 2018 Dec; 28(12):841-849. PubMed ID: 29983236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV Preexposure Prophylaxis, by Race and Ethnicity - United States, 2014-2016.
    Huang YA; Zhu W; Smith DK; Harris N; Hoover KW
    MMWR Morb Mortal Wkly Rep; 2018 Oct; 67(41):1147-1150. PubMed ID: 30335734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Willingness to Take, Use of, and Indications for Pre-exposure Prophylaxis Among Men Who Have Sex With Men-20 US Cities, 2014.
    Hoots BE; Finlayson T; Nerlander L; Paz-Bailey G;
    Clin Infect Dis; 2016 Sep; 63(5):672-7. PubMed ID: 27282710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vital Signs: Estimated Percentages and Numbers of Adults with Indications for Preexposure Prophylaxis to Prevent HIV Acquisition--United States, 2015.
    Smith DK; Van Handel M; Wolitski RJ; Stryker JE; Hall HI; Prejean J; Koenig LJ; Valleroy LA
    MMWR Morb Mortal Wkly Rep; 2015 Nov; 64(46):1291-5. PubMed ID: 26606148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of HIV Preexposure Prophylaxis Use Behaviors and HIV Incidence Among US Adults in an Integrated Health Care System.
    Hojilla JC; Hurley LB; Marcus JL; Silverberg MJ; Skarbinski J; Satre DD; Volk JE
    JAMA Netw Open; 2021 Aug; 4(8):e2122692. PubMed ID: 34436609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Cost-effectiveness Analysis of Preexposure Prophylaxis for the Prevention of HIV Among Los Angeles County Men Who Have Sex With Men.
    Drabo EF; Hay JW; Vardavas R; Wagner ZR; Sood N
    Clin Infect Dis; 2016 Dec; 63(11):1495-1504. PubMed ID: 27558571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health Care Facility Characteristics are Associated with Variation in Human Immunodeficiency Virus Pre-exposure Prophylaxis Initiation in Veteran's Health Administration.
    Maier MM; Gylys-Colwell I; Lowy E; Van Epps P; Ohl M; Chartier M; Beste LA
    AIDS Behav; 2019 Jul; 23(7):1803-1811. PubMed ID: 30547331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial.
    Deutsch MB; Glidden DV; Sevelius J; Keatley J; McMahan V; Guanira J; Kallas EG; Chariyalertsak S; Grant RM;
    Lancet HIV; 2015 Dec; 2(12):e512-9. PubMed ID: 26614965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlations of HIV Preexposure Prophylaxis Indications and Uptake, Chicago, Illinois, 2015-2018.
    Pyra M; Rusie LK; Baker KK; Baker A; Ridgway J; Schneider J
    Am J Public Health; 2020 Mar; 110(3):370-377. PubMed ID: 31944849
    [No Abstract]   [Full Text] [Related]  

  • 14. Roadblocks to PrEP: What Medical Records Reveal About Access to HIV Pre-exposure Prophylaxis.
    Skolnik AA; Bokhour BG; Gifford AL; Wilson BM; Van Epps P
    J Gen Intern Med; 2020 Mar; 35(3):832-838. PubMed ID: 31705471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study.
    Grulich AE; Guy R; Amin J; Jin F; Selvey C; Holden J; Schmidt HA; Zablotska I; Price K; Whittaker B; Chant K; Cooper C; McGill S; Telfer B; Yeung B; Levitt G; Ogilvie EE; Dharan NJ; Hammoud MA; Vaccher S; Watchirs-Smith L; McNulty A; Smith DJ; Allen DM; Baker D; Bloch M; Bopage RI; Brown K; Carr A; Carmody CJ; Collins KL; Finlayson R; Foster R; Jackson EY; Lewis DA; Lusk J; O'Connor CC; Ryder N; Vlahakis E; Read P; Cooper DA;
    Lancet HIV; 2018 Nov; 5(11):e629-e637. PubMed ID: 30343026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preexposure Prophylaxis for the Prevention of HIV Infection: Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Chou R; Evans C; Hoverman A; Sun C; Dana T; Bougatsos C; Grusing S; Korthuis PT
    JAMA; 2019 Jun; 321(22):2214-2230. PubMed ID: 31184746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study.
    Molina JM; Charreau I; Spire B; Cotte L; Chas J; Capitant C; Tremblay C; Rojas-Castro D; Cua E; Pasquet A; Bernaud C; Pintado C; Delaugerre C; Sagaon-Teyssier L; Mestre SL; Chidiac C; Pialoux G; Ponscarme D; Fonsart J; Thompson D; Wainberg MA; Doré V; Meyer L;
    Lancet HIV; 2017 Sep; 4(9):e402-e410. PubMed ID: 28747274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perspectives on HIV pre-exposure prophylaxis (PrEP) utilization and related intervention needs among people who inject drugs.
    Biello KB; Bazzi AR; Mimiaga MJ; Biancarelli DL; Edeza A; Salhaney P; Childs E; Drainoni ML
    Harm Reduct J; 2018 Nov; 15(1):55. PubMed ID: 30419926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methods for county-level estimation of pre-exposure prophylaxis coverage and application to the U.S. Ending the HIV Epidemic jurisdictions.
    Sullivan PS; Mouhanna F; Mera R; Pembleton E; Castel AD; Jaggi C; Jones J; Kramer MR; McGuinness P; McCallister S; Siegler AJ
    Ann Epidemiol; 2020 Apr; 44():16-30. PubMed ID: 32088073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-retroviral Therapy Based HIV Prevention Among a Sample of Men Who Have Sex with Men in Cape Town, South Africa: Use of Post-exposure Prophylaxis and Knowledge on Pre-exposure Prophylaxis.
    Hugo JM; Stall RD; Rebe K; Egan JE; De Swardt G; Struthers H; McIntyre JA
    AIDS Behav; 2016 Dec; 20(Suppl 3):357-364. PubMed ID: 27631366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.